Table 3—

Association of matrix metalloproteinase(MMP) single nucleotide polymorphisms and the response after the second cycle of chemotherapy for all lung cancer patients

PolymorphismGenotypesPatients nAll (n = 349)SCLC (n = 161)NSCLC (n = 187)Stage IIB+IIIA (n = 40)Stage IIIB (n = 98)Stage IV (n = 177)
MMP1
 G-1607GGG/G961 (ref)1 (ref)1 (ref)1 (ref)1 (ref)1 (ref)
G/GG+2530.9 (0.5–1.4)0.9 (0.3–2.1)1.0 (0.5–1.9)0.65 (0.13–3.31)1.03 (0.37–2.83)0.8 (0.4–1.4)
GG/GG
MMP2
 C-735TCC2661 (ref)1 (ref)1 (ref)1 (ref)1 (ref)1 (ref)
CT+TT811.5 (0.9–2.6)2.1 (0.9–4.8)1.5 (0.7–3.0)6.0 (1.1–31.3)#2.8 (1.1–7.4)1.0 (0.5–2.1)
MMP3
 6A-1171 5A6A 6A901 (ref)1 (ref)1 (ref)1 (ref)1 (ref)1 (ref)
6A 5A+5A 5A2591.4 (0.8–2.4)1.4 (0.6–3.4)1.2 (0.6–2.3)1.1 (0.20–8.48)10.4 (1.3–81.5)+0.9 (0.5–1.6)
MMP7
 C-153TCC2871 (ref)1 (ref)1 (ref)1 (ref)1 (ref)1 (ref)
CT+TT601.8 (1.0–3.2)2.2 (0.9–5.4)1.7 (0.8–3.9)6.0 (1.1–31.3)§1.54 (0.52–4.70)1.4 (0.6–2.9)
 A-181GAA661 (ref)1 (ref)1 (ref)1 (ref)1 (ref)1 (ref)
AG+GG2831.0 (0.6–1.8)1.0 (0.4–2.6)1.1 (0.5–2.2)1.3 (0.1–14.1)1.39 (0.41–4.62)0.7 (0.3–1.5)
MMP9
 C-1562TCC2611 (ref)1 (ref)1 (ref)1 (ref)1 (ref)1 (ref)
CT+TT870.9 (0.5–1.5)1.2 (0.5–2.8)0.7 (0.4–1.4)2.0 (0.4–10.8)0.6 (0.1–2.1)1.0 (0.5–1.9)
MMP12
 A-82GAA541 (ref)1 (ref)1 (ref)1 (ref)1 (ref)1 (ref)
AG+GG940.9 (0.5–1.5)0.8 (0.3–1.8)1.3 (0.7–2.7)0.9 (0.2–5.3)1.0 (0.3–2.6)0.8 (0.4–1.5)
 A1082GAA3081 (ref)1 (ref)1 (ref)1 (ref)1 (ref)1 (ref)
AG+GG400.7 (0.3–1.4)0.4 (0.1–1.7)1.0 (0.4–2.7)0.5 (0.0–4.1)N/A1.1 (0.5–2.7)
  • Data presented as OR (95% CI), unless otherwise stated. Genotype results are missing for MMP2 C-735T, MMP7 C-153T (two patients each), MMP9 C-1562T, MMP12 A-82G, MMP12 A1082G (one patient each). ORs were adjusted for stage. SCLC: small cell lung cancer; NSCLC: nonsmall cell lung cancer; N/A: not applicable. Bold indicates significance. #: p = 0.03; : p = 0.02; +: p = 0.01; §: p = 0.03.